Xilio Revenue Jumps 246 Percent in Q2
Xilio Therapeutics (NASDAQ:XLO), a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies, reported its Q2 2025 results on August 14, 2025. The company reported collaboration and license revenue (GAAP) of $8.1 million, up sharply from $2.4 million (GAAP) in Q2 2024 but missed the analyst consensus of $8.21 million (GAAP) by 1.3%. Net loss was $15.8 million, as research and development expense continued to rise. Despite this, Xilio ended the quarter with $121.6 million in cash and cash equivalents, more than double its balance at year-end 2024. The period highlights rapid advancement of the clinical pipeline, key partnership developments, and though operating losses (GAAP net loss) also increased.
Source: Analyst estimates for the quarter provided by FactSet.
Xilio Therapeutics focuses on developing immuno-oncology treatments using its platform for tumor-activated or "masked" drugs. This approach aims to activate therapies specifically within tumors, limiting the unwanted effects often seen with cancer immunotherapies. The flagship products in its pipeline are vilastobart, an anti-CTLA-4 antibody, and XTX301, a tumor-activated version of interleukin-12 (IL-12).
Source Fool.com
